|1.||Dinarello, Charles A: 20 articles (08/2015 - 10/2003)|
|2.||Abbate, Antonio: 13 articles (02/2015 - 02/2002)|
|3.||Gabay, Cem: 12 articles (05/2012 - 03/2002)|
|4.||Rothwell, Nancy J: 11 articles (05/2014 - 10/2003)|
|5.||Iwakura, Yoichiro: 11 articles (01/2014 - 08/2003)|
|6.||Netea, Mihai G: 9 articles (10/2015 - 02/2006)|
|7.||Rigante, Donato: 9 articles (07/2015 - 11/2006)|
|8.||Goldbach-Mansky, Raphaela: 9 articles (11/2013 - 08/2006)|
|9.||Martini, Alberto: 8 articles (11/2015 - 09/2007)|
|10.||Isoda, Kikuo: 8 articles (01/2014 - 08/2003)|
01/01/2013 - "First-line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra. "
06/01/2012 - "Therapy with anakinra was initiated, with rapid clearance of skin lesions and resolution of systemic inflammation. "
11/01/2013 - "Skin findings promptly improved upon initiation of treatment with anakinra (recombinant human IL-1 receptor antagonist), and the bony lesions and systemic inflammation resolved with continued therapy. "
07/01/2002 - "IL-1Ra and vIL-10 gene transfer using retroviral vectors ameliorates particle-associated inflammation in the murine air pouch model."
05/01/2012 - "This study demonstrates that IL-1Ra plays an important role in suppressing local responses in eyes injected with LPS and that there is discordance between murine eyes and joints in the extent to which IL-1Ra protects against spontaneous inflammation."
01/01/2007 - "Our clinical experience confirms that anakinra is effective and safe in the treatment of rheumatoid arthritis. "
05/01/2004 - "This article reviews the preclinical, clinical, and postmarketing data on the safety and efficacy of anakinra in the treatment of rheumatoid arthritis and focuses on the pivotal clinical trials that led to FDA approval."
09/01/2002 - "A large, prospective safety study which allowed a wide-variety of comorbid conditions and concomitant medications demonstrated that anakinra therapy is a well-tolerated treatment for rheumatoid arthritis in the patient population seen by the practicing rheumatologist. "
07/01/2002 - "Anakinra shows promise for treating patients with rheumatoid arthritis."
07/01/2014 - "In a double-blind crossover trial, 80 patients with rheumatoid arthritis (60 with CAD and 20 without) were randomized to a single injection of anakinra or placebo and after 48 hours to the alternative treatment. "
02/01/2000 - "This gene therapy, by combining highly efficient and stable rAAV gene delivery, disease-regulated gene expression, and the antiinflammatory effect of IL-1Ra, provides a valuable approach for long-term protection against, and prevention of, arthritis."
01/01/2003 - "Daily administration of recombinant IL-1Ra, injected at the same time as arthritis induction, is effective in blocking the occurrence of inflammatory as well as destructive changes in CIA. "
01/01/2015 - "Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature."
01/01/2001 - "Recombinant human IL-1Ra (rhu-IL-1Ra) has been evaluated in RA in several randomised clinical trials and was shown to significantly reduce both the clinical manifestations of arthritis and the rate of progressive joint damage. "
07/01/1996 - "The IL-1Ra Arthritis Study Group."
|4.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
11/01/2012 - "Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)."
08/01/2015 - "To assess anakinra as a therapy for systemic juvenile idiopathic arthritis (sJIA) in a single-center series. "
08/01/2015 - "Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience."
01/01/2013 - "Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes. "
01/01/2013 - "Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes."
|5.||Adult-Onset Still's Disease
05/01/2013 - "Anakinra is effective in adult-onset Still's disease (AOSD) in the short term, but little is known regarding its efficacy over the long term. "
05/01/2008 - "Effective treatment of steroid refractory adult-onset Still's disease with anakinra."
09/01/2015 - "Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review."
06/01/2007 - "Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial."
04/01/2015 - "We report a 46-year-old white woman with adult-onset Still's disease (AOSD) treated with anakinra, a IL-1B receptor antagonist. "
|1.||Interleukin-1 (Interleukin 1)
|2.||Interleukin-1 Receptors (Interleukin 1 Receptor)
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||Adrenal Cortex Hormones (Corticosteroids)
|6.||Interleukin-6 (Interleukin 6)
|8.||TNFR-Fc fusion protein (etanercept)